KOL Views: Can apalutamide and/or Xtandi change non-metastatic CRPC practice patterns?

Data from the SPARTAN trial of Johnson & Johnson’s apalutamide and PROSPER study of Astellas/Pfizer’s Xtandi (enzalutamide) suggested the agents are more similar than different in non-metastatic patients with castration-resistant prostate cancer (nmCRPC). Both androgen receptor blockers significantly prolonged the primary endpoint of metastasis-free survival (MFS), whereas overall survival (OS) data only trended in the right direction. This begs the question of whether one or both are effective enough to make inroads in the indication.

To provide FirstWord readers with rapid feedback on apalutamide and Xtandi’s prospects in nmCRPC, we are hosting an expert call with a key opinion leader (KOL) early next week.

Key topics that will be discussed during the call include, among other things… feedback on the SPARTAN and PROSPER results; do the data indicate any notable differences between apalutamide and Xtandi; thoughts on relevance of MFS as an approvable endpoint, how big is the commercial opportunity in nmCRPC and how is it likely to change in the coming years; should apalutamide and Xtandi be approved in this indication and, if so, how and when would you use them; how disappointing is the lack of overall survival benefit and will this impact use; what are the most important factors that may stand in the way of adoption?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving and highly competitive treatment paradigm in prostate cancer.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more ViewPoints articles, click here.